Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp Equity Growth

The Year-over-Year Equity Growth of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Nov 12, 2026 is 3.10 %. In the previous year, Year-over-Year Equity Growth was -2.42 % — a change of -228.39% (higher).

Equity Growth

3.10 %

YoY

-228.39%

Last updated:

Year-over-Year Equity Growth of Vcanbio Cell & Gene Engineering Corp is 2025 3.10 % . Year-over-Year Equity Growth of Vcanbio Cell & Gene Engineering Corp was 2024 -2.42 % . It decreases by -228.39% higher compared to the previous year.

The Vcanbio Cell & Gene Engineering Corp Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
83.73 CNY
Jan 1, 2019
20.96 CNY
Jan 1, 2020
1.83 CNY
Jan 1, 2021
1.42 CNY
Jan 1, 2022
2.67 CNY
Jan 1, 2023
3.61 CNY
Jan 1, 2024
-2.42 CNY
Jan 1, 2025
3.10 CNY
The Vcanbio Cell & Gene Engineering Corp Equity Growth history
YEAREquity GrowthYoY
3.10 %-228.39%
-2.42 %-166.96%
3.61 %+35.28%
2.67 %+87.97%
1.42 %-22.40%
1.83 %-91.28%
20.96 %-74.97%
83.73 %-1,786.90%
-4.96 %-324.37%
2.21 %-95.62%
50.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp., Ltd. generates revenue through the development and sale of life sciences technology products. The company produces cytokines culture solutions, cosmetics, and detection reagents for domestic markets. Its business segments include cell culture, gene detection and storage, and the production of specialized biological products. The firm's domestic customers primarily purchase these products for research and commercial applications in the life sciences sector. Vcanbio focuses on cell culture and gene detection services, which are integral to its product offerings. The company's cytokines culture solutions are sold to domestic clients in the biotechnology and pharmaceutical industries. Detection reagents are also marketed to domestic laboratories and healthcare providers for diagnostic purposes. The firm leverages its 2,332 full-time employees to support research, development, and production activities. The company's product portfolio includes cosmetics alongside scientific reagents, targeting both consumer and professional markets. Domestic markets remain the primary focus for all sales, with no mention of international operations. Vcanbio's revenue streams are derived from the sale of its core products, which are developed and manufactured in-house. Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

Year-over-Year Equity Growth of Vcanbio Cell & Gene Engineering Corp is 3.10 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Vcanbio Cell & Gene Engineering Corp historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — Vcanbio Cell & Gene Engineering Corp

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Vcanbio Cell & Gene Engineering Corp